Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Papp

Showing results (91-100 of 137) with videos related to

Pageof 14
Sort By:
Journal of Drugs in Dermatology : JDD|October 17, 2017
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With PsoriasisRobert Bissonnette, Francisco Kerdel, Luigi Naldi, et al.
Arthritis and Rheumatism|April 1, 2009
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthur Kavanaugh, Iain McInnes, Philip Mease, et al.
The New England Journal of Medicine|February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque PsoriasisRobert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
Journal of the American Academy of Dermatology|August 3, 2021
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trialLinda Stein Gold, Kim Papp, David Pariser, et al.
European Journal of Dermatology : EJD|April 4, 2006
Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severityPeter C M van de Kerkhof, Knud Kragballe, Joar Austad, et al.
Journal of the American Academy of Dermatology|December 27, 2022
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
BMC Rheumatology|March 20, 2019
Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registryArthur Kavanaugh, Kim Papp, Alice B Gottlieb, et al.
Rheumatology (Oxford, England)|October 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 studyAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.
Clinical and Experimental Rheumatology|July 5, 2023
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 studyPhilip Mease, Arathi Setty, Kim Papp, et al.
Pageof 14

Showing results (91-100 of 137) with videos related to

Sort By:
Pageof 14
Journal of Drugs in Dermatology : JDD|October 17, 2017
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With PsoriasisRobert Bissonnette, Francisco Kerdel, Luigi Naldi, et al.
Arthritis and Rheumatism|April 1, 2009
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthur Kavanaugh, Iain McInnes, Philip Mease, et al.
The New England Journal of Medicine|February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque PsoriasisRobert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
Journal of the American Academy of Dermatology|August 3, 2021
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trialLinda Stein Gold, Kim Papp, David Pariser, et al.
European Journal of Dermatology : EJD|April 4, 2006
Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severityPeter C M van de Kerkhof, Knud Kragballe, Joar Austad, et al.
Journal of the American Academy of Dermatology|December 27, 2022
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
BMC Rheumatology|March 20, 2019
Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registryArthur Kavanaugh, Kim Papp, Alice B Gottlieb, et al.
Rheumatology (Oxford, England)|October 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 studyAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.
Clinical and Experimental Rheumatology|July 5, 2023
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 studyPhilip Mease, Arathi Setty, Kim Papp, et al.
Pageof 14